TARA

Protara Therapeutics, Inc. [TARA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TARA Stock Summary

Top 10 Correlated ETFs

TARA

Top 10 Correlated Stocks

TARA

In the News

TARA Financial details

Company Rating
-
Market Cap
34.3M
Income
-39.73M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
26
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-0.4
Forward P/E
-
PEG
0.1
P/S
-
P/B
0.36
P/C
-
P/FCF
-1.02
Quick Ratio
10.93
Current Ratio
11.49
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.51
EPS next Y
-
EPS next Q
-
EPS this Y
-38.02%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
3.45%
-
-
-
-
SMA20
25%
SMA50
66.67%
SMA100
66.67%
Inst Own
-
Inst Trans
-
ROA
-77%
ROE
-76%
ROC
-0.15%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.04-5.24
52W High
+1.7%
52W Low
+408.5%
RSI
58
Rel Volume
1.33
Avg Volume
229.16K
Volume
304.96K
Perf Week
-7.38%
Perf Month
65.64%
Perf Quarter
51.79%
Perf Half Y
17.71%
-
-
-
-
Beta
1.877
-
-
Volatility
0.17%, 0.78%
Prev Close
-0.29%
Price
5.085
Change
-2.59%

Something similar

Top by Market Cap
META
1YD.DE
GOOG
JPM
VFINX
Top Correlated ETFs
IUSU.L
XLUP.L
IDU
UPW
IUUS.L
Top Correlated Stocks
NEE
EDPR.LS
RWE.DE
0K80.L
PHSP.L
Similar Market Cap
OCC
HFUS
EAOA
QCORE.ST
SAMAU

Company Profile

Healthcare Biotechnology
  • Volume Average 229.16K
  • Market Capitalization 34.3M
  • Employee 26
  • CEO Mr. Jesse Shefferman
  • Headquarters New York,NY,US
  • IPO Date 2014-10-22
  • Website https://www.protaratx.com

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.